Microarrays for gene expression profiling offers important research tools for novel classification of leukemia's and lymphomas, which may have implications for prognosis and treatment.
1,2 In the field of hematologic malignancies, several papers have demonstrated that the use of microarrays indeed may provide novel information at diagnosis. Using Affymetrix oligonucleotide microarrays, distinct expression profiles have been described for the different cytogenetically defined subgroups of acute lymphoblastic leukemia (ALL).
2 Subsequently, also prognostic and disease progression markers have been proposed, ultimately leading to the prospect of patient-tailored therapy.
2 However, so far no clear prognostic profiles have been defined. In addition, microarray-based comparisons of paired diagnosis-relapse samples 3-5 from patients with B-precursor ALL have been performed, but so far, not many studies have used this approach. Also, some studies focussed on the identification of glucocorticoid-response genes in children with ALL, comparing diagnosisFday 8 gene expression profiles. 6, 7 Treatment of pediatric ALL is increasingly based on the concept of tailoring the intensity of treatment to the risk of treatment failure or success.
Clinical studies have shown that it is possible to stratify patients according to the levels of minimal residual disease (MRD) after induction therapy and early during further treatment, as it has been demonstrated that the MRD level is the best predictive level for disease outcome. In previous studies we reported that slow responding subclones represent the clones causative for leukemic relapse in oligoclonal disease. 8, 9 On the basis of these results, we now hypothesize that the gene expression profile of the slowresponding subclones still present after the first weeks of chemotherapy might be different from the profiles of all leukemic cells at diagnosis, and are more predictive for outcome as subclones are being selected during induction therapy.
To study these differences in the expression profiles of leukemic cells, we selected 26 genes (5 genes from Staal et al.
3 and 21 top-ranked genes from Beesley et al. 4 ) that showed differential expression in diagnosis and relapse, originating from the above-mentioned studies that compared gene expression levels between diagnosis and relapse in B-precursor ALL.
Gene sequences (mRNA and genomic DNA) were obtained from public databases NCBI (http://www.ncbi.nlm.nih.gov) and BLAT (http://genome.ucsc.edu/cgi-bin/hgBlat). Primer design was performed using Primer Express 2.0 and Oligo6. Finally, for 23 genes, adequate primers were designed, showing specific amplification (Table 1) .
Paired diagnosis-day15-relapse samples from three relapsed B-precursor ALL patients were analyzed. On the basis of the markers expressed on the tumor cells (CD34, CD19, and CD10) cryopreserved mononuclear cells obtained from Ficoll density centrifugation before cryopreservation, were purified using an MOFlo High Performance Cell Sorter. Total RNA was extracted from these cell subsets following the TRIZOL protocol, subsequently followed by cDNA synthesis. RNA integrity was assessed using an Agilent 2100 BioAnalyser (Santa Clara, CA, USA). The expression levels of 23 genes were determined in a SYBR Green based real-time PCR assay.
All Ct values were normalized to b-glucuronidase (GUS) expression. We compared the expression levels in diagnosis and relapse samples. Per patient the genes were divided into three groups: two groups of markers in which the expression level at relapse was at least either two times higher or two times lower than at diagnosis resulting in DCt 41; respectively o1 (DCt ¼ normalized Ct at diagnosisÀnormalized Ct at relapse), and a group in which the difference between diagnosis and relapse was within a factor 2 (range DCt: À1 to þ 1). It should be noted that the observed changes in expression level for the different genes varied between the patients and were in some cases more than 10-fold. As can be seen from figures, the expression level of 21 out of 26 genes that were downregulated at relapse (Figure 1) were also lower at day 15, and vice versa 8 out of 11 genes that were upregulated ( Figure 2 ) were also more highly expressed at day 15.
As a control served the group of 26 genes that showed hardly any difference in our diagnosis and relapse samples, and indeed the expression level of most of these genes (23 out of 26) were not different at day 15 ( Figure 3) .
We conclude that in this small number of patients, there is at least a trend that the expression level changes during early treatment toward the expression level observed at relapse. Although one might argue that this change in expression is induced by a direct effect of chemotherapy or corticosteroids on the leukemic cells, 6, 7 we assume that the expression profiles are not influenced by this effect. We selected genes showing differences between diagnosis and relapse, both time points at which there will be no direct effect of therapeutic agents on the expression level. In fact, our observation that the selected genes behaved differently in the different patients, depending on the expression level in the relapsing clone, is an extra argument against the possibility that the observed change in expression level is due to therapy. Therefore, our hypothesis that the expression level at day 15 is different from diagnosis and might resemble more the expression profile at relapse is supported by this pilot experiment. We postulate that this change in gene signature is caused by selection of therapy resistant subclones in the first weeks of treatment. As the gene signature of these therapy resistant subclones can be masked at diagnosis by the presence of an Figure 1 Genes downregulated at relapse with DCt o1.
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Oligonucleotide sequences of forward (fw) and reverse (rev) primers and probe used for real-time quantitative PCR
excess of therapy sensitive leukemic cells, we expect that the expression profile of leukemic cells present after 2 weeks of therapy will be more predictive for relapse than the profile obtained at diagnosis. On the basis of what is stated above, we will analyze gene expression profiles by microarray studies on purified leukemic cells at day15 of treatment. These results will lead to further studies to understand the pathological background of ALL. Second, a gene signature based on microarray analysis associated with residual disease assessment during early treatment, will help identifying patients with a high risk for relapse resulting in better treatment stratification. Figure 3 Genes upregulated or downregulated at relapse with range DCt: À1 to þ 1. We read with interest the recent comments of Steinbach and Debatin 1 concerning the definition of 'sensitivity' with regard to minimal residual disease (MRD). What is usually meant by 'sensitivity' may be described more accurately as the estimated lower limit of detection of MRD. Although Steinbach and Debatin 1 write from the perspective of acute leukaemia, our experience is in the monitoring of chronic myeloid leukaemia. Recognizing important differences in the biology and treatment of acute and chronic leukaemia, there remain certain common principles of MRD monitoring that we wish to address. In particular, we emphasize that the limit of detection of MRD is dependent on (1) the performance characteristics of the analytical system and (2) the quality of the individual sample analysed.
Steinbach and Debatin 1 suggest that the term 'sensitivity' should be reserved to describe test sensitivity (number of test positives divided by true positives), but this definition may be impractical. First, sensitivity can be calculated only if the number of true positives (true test positives þ false negatives) is known. In acute leukaemia, the 'gold standard' indicator of the presence of MRD is relapse, and this can only be determined in retrospect. The estimation of test sensitivity using serial dilutions of cell lines with known cell numbers is possible, but this estimate of sensitivity may not be accurate when applied to patient samples. For instance, in the setting of chronic myeloid leukaemia MRD, the widely used K562 cell line has multiple copies of the BCR-ABL gene in each cell 2 and expresses high levels of BCR-ABL mRNA. The choice of cell line for the determination of sensitivity will influence the result, 3 and the use of cell lines to define sensitivity may overestimate the lower limit of detection (or underestimate the MRD burden) when extrapolated to patient samples.
It has earlier been reported that an optimized quantitative PCR assay can detect a single intact copy of the target sequence if the target sequence is present. 4 In an MRD setting, the number of target copies is low. As the limit of detection is approached, stochastic effects become important. For example, if 1 mg DNA were to contain on average one copy of the leukaemic sequence (estimated MRD level 6 Â 10 -6 ), then the probability that MRD would be detected if 1 mg DNA were analysed is only 63%, according to Poisson statistics. To have 95% confidence that the true level of MRD is o6 Â 10 -6 , it would be necessary to perform the assay at least three times, using X3 mg DNA. In quantitative assays, there is an increase in imprecision at very low levels of MRD, whereas in qualitative assays discrepant results will be seen in replicate analyses performed on the same sample.
3,4 The number of replicate analyses performed, and the total amount of sample analysed, are critical determinants of the lower limit of detection achieved in any assay system. The estimated lower limit of detection of an assay should therefore include an indication of the amount of material used (for example, mg amount of DNA or RNA) and the number of replicate analyses.
In the field of chronic myeloid leukaemia, the potential to extend the detection limit of MRD by multiple replicate analyses was demonstrated by the identification of rare BCR-ABL transcripts in the blood of some normal individuals. 5 In a diagnostic laboratory processing large numbers of clinical samples, the risk of cross-contamination between patients expressing the same leukaemic mRNA transcript might preclude the use of such extremely sensitive PCR methods. Using genomic DNA PCR, on the other hand, there may be considerable interpatient diversity in the sequence of the MRD target (for example, immunoglobulin gene variable regions). In this setting, an MRD assay will be less susceptible to crosscontamination and it might be practical to use 30-40 replicates to increase sensitivity by 10-fold.
It is self-evident that the optimization of an assay system is irrelevant if the actual sample analysed is highly degraded. The problem of degradation of mRNA is well recognized, 6 but DNA may also be subject to degradation. 7 In addition, endogenous and exogenous substances (for example, heparin) in patient samples may be inhibitory to PCR. Therefore, an accurate estimation of the lower limit of detection of MRD by PCR methods should include a measurement of the amount of intact, amplifiable nucleic acid. In the monitoring of chronic myeloid leukaemia by quantitative real-time reverse transcriptase PCR, the control genes BCR, ABL and GUSB are commonly quantified in cDNA in parallel with the target BCR-ABL sequence to give an indication both of sample quality and of reverse transcription efficiency. 8 In genomic DNA, a control sequence could be selected on the basis that its sequence and copy number are not altered in leukaemic cells. The quantification of a control gene provides invaluable information about sample quality and should ensure that the level of MRD is not underestimated due to the use of sub-optimal samples.
In summary, the standardized reporting of the estimated lower limit of detection of PCR assays for leukaemia MRD is highly desirable, but should take into account (1) the amount of DNA or RNA in each assay and the number of replicates performed; and (2) the quality of the individual patient sample analysed. 
DM
